Dongyang Tang

Dr. Dongyang Tang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
DTDongyang Tang
Dongyang Tang
XZXin Zhao
Xin Zhao
LZLi Zhang
Li Zhang
ZWZhiwei Wang
Zhiwei Wang
Cheng WangCheng Wang
Cheng Wang

4 April 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
XZXin Zhao
Xin Zhao
DTDongyang Tang
Dongyang Tang
XZXu Zuo
Xu Zuo
TZTian‐Dong Zhang
Tian‐Dong Zhang
Cheng WangCheng Wang
Cheng Wang

24 January 2017 in Bioprocess and Biosystems Engineering
Verified
Journal Article
Closed access
PDF file
XCXiaofei Chen
Xiaofei Chen
RCRong Chen
Rong Chen
XYXiaoxiao Yu
Xiaoxiao Yu
DTDongyang Tang
Dongyang Tang
WYWenbing Yao
Wenbing Yao
XGXiangdong Gao
Xiangdong Gao

9 September 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
BWBin Wang
Bin Wang
DTDongyang Tang
Dongyang Tang
ZZZiyang Zhang
Ziyang Zhang
ZWZhiwei Wang
Zhiwei Wang

15 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
XZXin Zhao
Xin Zhao
DTDongyang Tang
Dongyang Tang
XCXiaofei Chen
Xiaofei Chen
SCShaoqing Chen
Shaoqing Chen
Cheng WangCheng Wang
Cheng Wang
Introduction. Baicalein has been shown to have antitumor activities in several cancer types. However, its acting mechanisms remain to be further investigated. This work is aimed at exploring the functional long noncoding RNA (lncRNA)/microRNA (miRNA)/messenger RNA (mRNA) triplets in response to baicalein in hepatocellular carcinoma (HCC) cell to understand the mechanisms of baicalein in HCC. Methods. Differentially expressed lncRNAs (DELs) and miRNAs (DEMs) in HCC cell treated with baicalein were first screened using GSE95504 and GSE85511, respectively. miRNA targets for DELs were predicted and intersected with DEMs, after which the miRNA expression was validated using ENCORI and its prognostic value was assessed using Kaplan‐Meier plotter. Potential miRNA targets were predicted by 3 prediction tools, after which expression level was validated at UALCAN and Human Protein Atlas. Kaplan‐Meier plotter was used to evaluate the effects of these genes on overall survival and recurrence‐free survival of HCC patients. Enrichment analyses for these genes were performed at DAVID. Results. Here, we identified 14 overlapping DELs and 26 overlapping DEMs in the baicalein treatment group than those in the DMSO treatment group. Subsequently, by analyzing expression and clinical significance of miRNAs, hsa‐miR‐4443 was found as a highly potential miRNA target. Then, targets of hsa‐miR‐4443 were predicted and analyzed, and we found AKT1 was the most potential target for hsa‐miR‐4443. Hence, the lncRNAs‐hsa‐miR‐4443‐AKT1 axis that can respond to baicalein was established. Conclusion. Collectively, we elucidated a role of lncRNAs‐hsa‐miR‐4443‐AKT1 pathway in response to baicalein treatment in HCC, which could help us understand the roles of baicalein in inhibiting cancer progression and may provide novel insights into the mechanisms behind HCC progression.

27 January 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
DTDongyang Tang
Dongyang Tang
XZXin Zhao
Xin Zhao
LZLi Zhang
Li Zhang
Cheng WangCheng Wang
Cheng Wang